Effects of Leuprorelin combined with Levonorgestrel-releasing intrauterine system in treatment of patients with adenomyosis
Objective:To observe the effect of leuprolide combined with Levonorgestrel-releasing intrauterine system in the treatment of patients with adenomyosis.Methods:A prospective study was conducted on 87 patients with adenomyosis admitted to the hospital from May 2021 to January 2023.According to the random number table method,they were divided into control group(43 cases)and observation group(44 cases).The control group was treated with Levonorgestrel-releasing intrauterine system,while the observation group was treated with Leuprorelin on the basis of that of the control group.Both groups were treated continuously for 6 months.The clinical efficacy,the uterine volume,the menstrual volume[pictorial blood loss assessment chart(PBAC)],the dysmenorrhea[visual analogue scale(VAS)]score,the serological indexes[carbohydrate antigen 19-9(CA19-9),carbohydrate antigen 125(CA125),prostaglandin F2α(PGF2α)]levels before and after the treatment,and incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the observation group was 97.73%(43/44),which was higher than 81.40%(35/43)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the uterine volume of the observation group was smaller than that of the control group,the PBAC and VAS scores were lower than those of the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of CA19-9,CA125 and PGF2α in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Leuprorelin combined with Levonorgestrel-releasing intrauterine system in the treatment of adenomyosis can improve the total effective rate of treatment,reduce the uterine volume and reduce the menstrual volume,the dysmenorrhea scores and the serological index levels.Moreover,it is superior to simple Levonorgestrel-releasing intrauterine system.
万方数据
维普
